Action OLMA OLEMA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Olema Pharmaceuticals, Inc.

Actions

OLMA

US68062P1066

Temps réel estimé Cboe BZX
Autres places de cotation
 19:38:06 16/07/2024 		Varia. 5j. Varia. 1 janv.
14,6 USD +11,07 % Graphique intraday de Olema Pharmaceuticals, Inc. +26,13 % +3,56 %
12/07 GoodRx Holdings, Inc. annonce l'élection de Ian T. Clark à son conseil d'administration CI
15/05 Olema Pharmaceuticals, Inc. annonce de nouvelles données prometteuses sur le palazestrant en association avec le ribociclib, présentées au 2024 Esmo Breast Cancer Congress CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology to Participate in Upcoming Investor Conferences in June
GL
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GL
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology to Participate in Upcoming Investor Conferences in May
GL
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
GL
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
GL
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
AQ
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Olema Oncology to Participate in Upcoming Investor Conferences
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
GL
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action OLMA
  4. Actualités Olema Pharmaceuticals, Inc.
  5. Communiqués